The Human Insulin Drugs Market is expected to register a CAGR of 4.56% during the forecast period of 2020-2025.
Top major leading players in the insulin Drug market are Novo Nordisk AS, Eli Lilly and Company, Biocon Limited, Julphar, Albireo Pharma, Inc., Sedico, Wockhardt Limited, and Pfizer, Inc.
Novo Nordisk is developing first once-weekly long-acting insulin (LAI287) which is currently in phase 2. The insulin is indicated for both type-1 and type-2 diabetes patients. Eli Lilly is developing a long-acting insulin-Fc (LY3209590). "Basal insulin-Fc" is a large molecule comprised of engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.
Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus, providing a more convenient, effective, as well as a safer method for delivering insulin therapy.
Sanfoli may 2020 Hanmi Pharmaceutical’s diabetes drug candidate efpeglenatide, which had led to a massive licensing deal with Sanofi, is on the brink of being discarded in the middle of the middle of phase 3 trial. On Thursday, the company announced that the French multinational drugmaker abruptly decided to return all rights concerning to Hanmi.
Frequent needle sticks to test blood sugar are a crucial, but sometimes unpleasant part of the daily diabetes routine. Testing your blood sugar helps you make decisions about what you eat, exercise, and insulin dosing. Continuous glucose monitoring, or CGM, helps you avoid the stick. It measures your blood sugar every few minutes via a tiny sensor inserted under the skin of your belly or arm, and sends the results wirelessly to a pump, smartphone, or other device. The FreeStyle Libre was the first CGM system to not require a finger stick. To get your blood sugar number, you simply wave a reader over the sensor.
In January 2020, Tandem Diabetes Care launched its t: slim X2 insulin pump with Control-IQ technology, which combines the Dexcom G6 CGM with an insulin pump to regulate insulin levels with little user effort. It’s the first system that both adjusts basal (background) insulin levels and delivers automatic bolus (mealtime) doses to prevent blood sugar from getting too low or too high. With the advent of CGM, the looking at a new phrase ‘time-in-range.’ That’s the percentage of the day a person spends with their blood sugar in the range their doctor wants them to be in. The monitor can check blood sugar every 5 minutes throughout the day, and it can catch fluctuations in a patient’s blood sugar that a finger stick can’t.
Based on type, the global human insulin market has been segmented into traditional human insulin and modern human insulin. By brand, has been segmented into Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin, and Insuman. By Application, Type I Diabetes and Type II Diabetes. Market has been categorized by region as the Americas, Europe, Asia-Pacific, and Middle East & Africa. North America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region because of a sedentary lifestyle. The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself. The United States accounts for the highest sales of the long-acting insulin, Lantus, across the world.